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Frozen plasma (FP) is commonly used for the treatment 
of bleeding or the prevention of bleeding in critically ill 
patients. In the acutely bleeding patient, there is no 
question that FP transfusions can be life saving, but the 
beneﬁ  t of FP transfusions in the prophylactic setting is 
much less clear, with a lack of high quality evidence to 
guide use. In a recent issue of Critical Care, Stanworth 
and colleagues [1] describe the clinical settings associated 
with FP transfusions in a rigorous prospective observa-
tional study in 29 UK general ICUs. Of 1,923 ICU admis-
sions, 13% of patients received FP transfusions for 404 FP 
treatment episodes; 24% of them were given in the 
absence of bleeding or requirement for an invasive proce-
dure, and with pre-transfusion international normalized 
ratios (INRs) that were essentially normal (INR <1.5, 
n = 32) or mildly deranged (INR 1.6 to 2.5, n = 65), which 
prompts the question of why these transfusions were 
given in the ﬁ   rst place. Although not all factors that 
contribute to a clinician’s decision to give an FP 
transfusion may have been captured in this study (for 
example, the presence of severe thrombocytopenia that 
may have further increased the perceived risk of bleed-
ing), it would appear that some of these transfusions were 
clearly inappropriate.
High rates of FP transfusions that are considered 
inappropriate are a consistent ﬁ   nding in audits of FP 
transfusions [2,3]. Th  is may seem surprising, especially 
given the concerns and public awareness regarding the 
harms associated with transfusion (particularly HIV and 
hepatitis C transmission, and more recently transfusion-
associated acute lung injury and transfusion-associated 
circulatory overload have been recognized). While the 
risk of transmitting HIV or hepatitis C is now rare 
(estimated at 1 in 3 to 4 million transfusions), there is 
mounting evidence of adverse events associated with FP 
transfusions in particular (increased new onset lung 
injury) [4] and excess ﬂ  uid administration in general in 
the critically ill [5,6]. For all these reasons, one might 
expect lower rates of inappropriate FP use.
A major diﬃ   culty in making decisions about whether 
to transfuse FP or not is that the clinical evidence to 
guide use of FP transfusions in the critically ill is currently 
sparse. Th   e few randomized clinical trials evaluating FP 
have not shown any beneﬁ  t for FP for prophylaxis and no 
other randomized controlled trials have evaluated the 
eﬀ  ectiveness of FP in reducing bleeding [7]. Clearly, more 
randomized controlled trials are needed so that we can 
base the decision to transfuse FP on good evidence.
In the absence of strong clinical evidence, critical care 
clinicians base their decisions to transfuse FP on their 
clinical rationale, balancing perceived potential risks with 
beneﬁ  ts, as well as with use of published FP transfusion 
guidelines that are not critical care speciﬁ  c. Th  e  common 
rationale for the transfusion of FP may be ﬂ  awed. First, 
abnormal coagulation tests do not necessarily represent 
an increased risk for blood loss. Th  e INR is a poor 
measure of the hemostatic level of individual coagulation 
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© 2011 BioMed Central Ltdproteins. With a single coagulation factor deﬁ  ciency, an 
INR of 1.5 represents a clinically important (<30%) 
reduction in that factor [8], but in situations where mul-
tiple coagulation factors are aﬀ  ected, such as in critically 
ill patients, the levels of the individual coagulation factors 
are suﬃ   cient for hemostasis (>30%) when the INR is 1.5 
and perhaps even higher [8]. Second, as was demon-
strated in the study of Stanworth and colleagues and 
others, FP transfusions do not result in signiﬁ  cant 
correction of the INR when the levels are mild to 
moderately increased [9,10]. Th   us, the question remains, 
at what INR level do we need to transfuse FP and what 
factors should modify our threshold? FP transfusion 
guidelines are general and they universally recommend 
FP use to be limited to instances when the INR is greater 
than 1.5 times normal and there is bleeding or risk of 
bleeding (that is, surgery or an invasive procedure) 
[11-13]. Th  is deﬁ  nition may qualify up to one-third of 
critically ill patients for an FP transfusion [14]. In the 
cohort of patients included in the study of Stanworth and 
colleagues, the rate of coagulopathic patients (30%) [14] 
is nearly twice the rate of patients transfused with FP 
(18%), which suggests variation in the decision to 
transfuse. Th   is variability may be explained by diﬀ  erences 
in patient-speciﬁ  c factors and/or variation in perceived 
risks of bleeding, factors that should be minimized by the 
generation of evidence that is speciﬁ  c and applicable to 
the critically ill.
In summary, the study by Stanworth and colleagues 
should aid to raise awareness of FP transfusion use in the 
critically ill and prompt a consideration of curbing FP use 
when it is not clearly appropriate. It also illustrates the 
need for further high quality evidence to guide FP use 
when the risk:beneﬁ  t ratio is less clear.
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